Multiple Sclerosis
Also known as: MS
Methodology & AI Transparency ⓘ
Multiple Sclerosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is multiple sclerosis? Multiple sclerosis (MS) is a disease that affects your brain and spinal cord , also called the central nervous system.
- 2 Real-world patient consensus: Diagnostic registry G35.D: Multiple Sclerosis is managed within Brain & Neurology (aka MS).
- 3 Typical cash cost range: Workup highlights for Multiple Sclerosis (G35.D): vascular stroke risk in Multiple Sclerosis (G35.D: stratification).
- 4 Top reported side effects / signs: Key Brain & Neurology biomarkers for Multiple Sclerosis (G35.D): Carotid Duplex / in Multiple Sclerosis (G35.D: Cerebral Perfusion) & HbA1c & Blood in Multiple Sclerosis (G35.D: Pressure Neuro-Targets) (BP < 120/75 mmHg; HbA1c < 5.7% (G35.D)).
Ask our AI Specialists anything about Multiple Sclerosis
What Is Multiple Sclerosis?
What is multiple sclerosis? Multiple sclerosis (MS) is a disease that affects your brain and spinal cord , also called the central nervous system. MS damages myelin, the protective coating around your nerve cells. Myelin helps nerves send messages quickly. When it's damaged, messages between your brain and body slow down or get blocked. This leads to MS symptoms. What are the types of multiple sclerosis? Not everyone with MS has the same experience. MS is grouped into types based on how the disease changes over time. Types of MS include: Relapsing-remitting MS . The most common type.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Multiple Sclerosis (G35.D, Brain & Neurology) reflects synaptic transmission alteration [Multiple Sclerosis G35.D]. Cross-referenced with NIH MeSH (Multiple Sclerosis), longitudinal control is benchmarked via Carotid Duplex / in Multiple Sclerosis (G35.D: Cerebral Perfusion).
Common Symptoms & Clinical Signs
- • Primary-progressive MS . Symptoms slowly worsen from the start, without clear relapses or periods of recovery
- • A previous infection with Epstein-Barr virus, which is the most common cause of mononucleosis (mono)
- • Presentation of Multiple Sclerosis (G35.D): episodic vertigo, imbalance, in Multiple Sclerosis (G35.D: coordination drift, or)
- • Secondary Multiple Sclerosis clinical sign: numbness, paresthesia, or in Multiple Sclerosis (G35.D: visual field/speech changes)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Multiple Sclerosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G35.D | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Carotid Duplex / in Multiple Sclerosis (G35.D: Cerebral Perfusion) | No hemodynamically significant stenosis (G35.D) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Blood in Multiple Sclerosis (G35.D: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (G35.D) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Multiple Sclerosis (G35.D: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (G35.D) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Multiple Sclerosis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Lovastatin Mevacor • RxCUI 197905 | HMG-CoA Reductase Inhibitor | 84% | $0.0421 | $ 5.69 /mo |
| Tecfidera (Dimethyl Fumarate) Tecfidera • RxCUI 1373483-B64406006 | Multiple sclerosis Agent | 91% | $0.9402 | $ 9.05 /mo |
| Natalizumab-Sztn Tyruko • RxCUI 2725173 | Integrin Receptor Antagonist | 93% | $0.9200 | $ 45.76 /mo |
| Adrenalin(R) Adrenalin(R) Generic • RxCUI 310132 | alpha-Adrenergic Agonist | 75% | $7.7955 | $ 185.00 /mo |
| Copaxone (Glatiramer Acetate) Copaxone • RxCUI 2000007-B68546325 | Multiple sclerosis Agent | 81% | $540.0503 | $ 992.50 /mo |
| Riluzole Tiglutik, Teglutik • RxCUI 2058147 | Benzothiazole | 90% | $0.2692 | $ 9.89 /mo |
| Fluorouracil Tolak, Efudex • RxCUI 105583 | Nucleoside Metabolic Inhibitor | 90% | $0.5853 | $ 16.50 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Multiple Sclerosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of: What a 1,156-Participant Study Found After accounting for therapeutic lag and differences between ASCEND and SPECTRIMS trials, natalizumab, compared. Journal of neurology, neurosurgery, and psychiatry • 2025-09-12 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 40050011 ↗ |
| New Insights on Utility of Progression Independent of Relapse Activity as a Trial Outcome in: What a 2,113-Participant Study Found Our analysis included 2,113 participants, 42.4% of whom developed radiologic disease activity during follow-up. Neurology • 2025-01-28 • Phase III Randomized Trial | N = 2,113 | 96/100 | PMID 39960455 ↗ |
| New Insights on Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for: What a 1,057-Participant Study Found Clinical and radiological outcomes generally favored DRF versus IFN. Journal of comparative effectiveness research • 2024-10-15 • Phase III Randomized Trial | N = 1,057 | 96/100 | PMID 39158844 ↗ |
| New Insights on Safety profile of efgartigimod from global clinical trials across multiple: What a 715-Participant Study Found Across clinical trials in IgG-mediated autoimmune diseases, efgartigimod was well tolerated with similar safety profiles regardless of dosing regimen. Expert review of clinical immunology • 2025-05-15 • Phase III Randomized Trial | N = 715 | 93/100 | PMID 40296516 ↗ |
| New Insights on Benefits and safety of Ponesimod Compared with Teriflunomide in Female Patients: What a 363-Participant Study Found Conclusions: Analyses demonstrate the real-world benefits and safety of ponesimod, versus active comparator, for women with relapsing MS, supporting data-informed decision-making for women with MS. Journal of women's health (2002) • 2024-04-15 • Phase III Randomized Trial | N = 363 | 93/100 | PMID 38301149 ↗ |
Multiple Sclerosis Patient Community & “People Like Me” Threads
Filter Multiple Sclerosis community threads and patient logs by age, biological sex, dosage, and treatment duration.